Table 1 Characteristics of the patients at baselinea
Characteristic | No. (%) | |
|---|---|---|
Ruxolitinib/steroids (n = 99) | Steroids only (n = 99) | |
Age, median (range), y | 35.0 (14.0–65.0) | 34.0 (14.0–64.0) |
Male | 65 (65.7) | 67 (67.7) |
Weight, median (range), kg | 64.0 (42.8–98.1) | 67.0 (42.2–118.0) |
Body-mass index, median (range), kg/m2 | 22.5 (16.0–32.8) | 23.3 (15.0–38.5) |
Diagnosis of underlying malignant disease | ||
Acute myelogenous leukemia | 54 (54.5) | 40 (40.4) |
Acute lymphoid leukemia | 28 (28.3) | 34 (34.3) |
Myelodysplastic syndrome | 5 (5.1) | 11 (11.1) |
Chronic myelogenous leukemia | 1 (1.0) | 2 (2.0) |
Non-Hodgkin lymphoma | 5 (5.1) | 3 (3.0) |
Other acute leukemia | 2 (2.0) | 5 (5.1) |
Other leukemia | 4 (4.0) | 4 (4.0) |
Disease Risk Index | ||
low | 15 (15.2) | 11 (11.1) |
Intermediate | 46 (46.5) | 48 (48.5) |
High | 32 (32.3) | 33 (33.3) |
Very High | 5 (5.1) | 6 (6.1) |
missing | 1 (1.0) | 1 (1.0) |
HCT-CI | ||
0 | 59 (59.6) | 47 (47.5) |
1 | 22 (22.2) | 40 (40.4) |
2 | 9 (9.1) | 5 (5.1) |
3 | 5 (5.1) | 3 (3.0) |
4 | 2 (2.0) | 3 (3.0) |
5 | 1 (1.0) | 0 (0.0) |
missing | 1 (1.0) | 1 (1.0) |
Time from diagnosis to HCT, median (range), d | 169 (12–859) | 212 (14–625) |
Time from HCT to screening, median(range), d | 25 (17–89) | 25 (15–77) |
Conditioning regimen | ||
Modified Bu/Cy | 85 (85.9) | 85 (85.9) |
Bu/Flu | 8 (8.1) | 10 (10.1) |
Modified TBI/Cy | 6 (6.1) | 4 (4.0) |
Donor’s age, median (range), y | 37 (14.0–63.0) | 34 (8.0–57.0) |
Donor-recipient ABO match | ||
Match | 56 (56.6) | 56 (56.6) |
Major mismatch | 21 (21.2) | 19 (19.2) |
Minor mismatch | 17 (17.2) | 18 (18.2) |
Bidirectional mismatch | 5 (5.1) | 6 (6.1) |
Donor-recipient gender match | ||
Female to male | 24 (24.5) | 19 (19.2) |
Female to female | 9 (9.1) | 9 (9.1) |
Male to female | 26 (26.3) | 23 (23.2) |
Male to male | 40 (40.4) | 48 (48.5) |
Graft | ||
MNCs, median (range), ×108/kg | 10.7 (2.8–28.0) | 10.3 (2.3–32.7) |
CD34+, median (range), ×106/kg | 4.9 (0.8–11.8) | 4.9 (0.9–20.0) |
Source of graft | ||
Matched sibling donor | 12 (12.1) | 10 (10.1) |
Haploidentical donor | 76 (76.8) | 78 (78.8) |
Unrelated donor | 11 (11.1) | 11 (11.1) |
Cytomegalovirus positive at HCT | 99 (100) | 99 (100) |
Donor cytomegalovirus positive at HCT | 99 (100) | 99 (100) |
Overall aGVHD grade at baselineb | ||
Grade II | 86 (86.9) | 88 (88.9) |
Grade III | 10 (10.1) | 6 (6.1) |
Grade IV | 3 (3.0) | 5 (5.1) |
aGVHD organ involvement at baseline | ||
Skin | 63 (63.6) | 72 (72.7) |
Liver | 6 (6.1) | 7 (7.1) |
Lower GI | 24 (24.2) | 30 (30.3) |
Biomarker risk at baselineb | ||
Intermediate | 55 (55.6) | 55 (55.6) |
High | 44 (44.4) | 44 (44.4) |
Overall aGVHD risk | ||
Minnesota high and biomarker high | 13 (13.1) | 11 (11.1) |
Minnesota standard and biomarker high | 31 (31.3) | 33 (33.3) |
Minnesota standard and biomarker intermediate | 55 (55.6) | 55 (55.6) |
Coadministrations of antifungal drugs | ||
Voriconazole | 83 (83.8) | 82 (82.8) |
Posaconazole | 8 (8.1) | 7 (7.1) |
Caspofungin | 8 (8.1) | 10 (10.1) |
